These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29296540)

  • 1. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.
    Harwood SL; Alvarez-Cienfuegos A; Nuñez-Prado N; Compte M; Hernández-Pérez S; Merino N; Bonet J; Navarro R; Van Bergen En Henegouwen PMP; Lykkemark S; Mikkelsen K; Mølgaard K; Jabs F; Sanz L; Blanco FJ; Roda-Navarro P; Alvarez-Vallina L
    Oncoimmunology; 2017; 7(1):e1377874. PubMed ID: 29296540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
    Mølgaard K; Harwood SL; Compte M; Merino N; Bonet J; Alvarez-Cienfuegos A; Mikkelsen K; Nuñez-Prado N; Alvarez-Mendez A; Sanz L; Blanco FJ; Alvarez-Vallina L
    Cancer Immunol Immunother; 2018 Aug; 67(8):1251-1260. PubMed ID: 29869168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.
    Tapia-Galisteo A; Sánchez Rodríguez Í; Aguilar-Sopeña O; Harwood SL; Narbona J; Ferreras Gutierrez M; Navarro R; Martín-García L; Corbacho C; Compte M; Lacadena J; Blanco FJ; Chames P; Roda-Navarro P; Álvarez-Vallina L; Sanz L
    Oncoimmunology; 2022; 11(1):2034355. PubMed ID: 35154908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
    Aschmoneit N; Kühl L; Seifert O; Kontermann RE
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
    Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
    Aschmoneit N; Steinlein S; Kühl L; Seifert O; Kontermann RE
    Sci Rep; 2021 Jul; 11(1):13880. PubMed ID: 34230555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers.
    Wang N; Patel H; Schneider IC; Kai X; Varshney AK; Zhou L
    Antib Ther; 2021 Apr; 4(2):90-100. PubMed ID: 34169228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.
    Ahmed M; Cheng M; Cheung IY; Cheung NK
    Oncoimmunology; 2015 Apr; 4(4):e989776. PubMed ID: 26137406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. eIg-based bispecific T-cell engagers targeting EGFR: Format matters.
    Kühl L; Schäfer AK; Kraft S; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2023; 15(1):2183540. PubMed ID: 36864566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A HER2 bispecific antibody can be efficiently expressed in
    Lin L; Li L; Zhou C; Li J; Liu J; Shu R; Dong B; Li Q; Wang Z
    Oncol Lett; 2018 Jul; 16(1):1259-1266. PubMed ID: 29963199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a Novel Bispecific Antibody That Activates T Cells
    Chornoguz O; Leettola CN; Leander K; Brosnan K; Emmell E; Chiu ML; Santulli-Marotto S
    Monoclon Antib Immunodiagn Immunother; 2019 Dec; 38(6):242-254. PubMed ID: 31825302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
    Seckinger A; Majocchi S; Moine V; Nouveau L; Ngoc H; Daubeuf B; Ravn U; Pleche N; Calloud S; Broyer L; Cons L; Lesnier A; Chatel L; Papaioannou A; Salgado-Pires S; Krämer S; Gockel I; Lordick F; Masternak K; Poitevin Y; Magistrelli G; Malinge P; Shang L; Kallendrusch S; Strein K; Hose D
    J Hematol Oncol; 2023 Dec; 16(1):117. PubMed ID: 38087365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.